PE20130386A1 - Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica - Google Patents
Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeuticaInfo
- Publication number
- PE20130386A1 PE20130386A1 PE2013000019A PE2013000019A PE20130386A1 PE 20130386 A1 PE20130386 A1 PE 20130386A1 PE 2013000019 A PE2013000019 A PE 2013000019A PE 2013000019 A PE2013000019 A PE 2013000019A PE 20130386 A1 PE20130386 A1 PE 20130386A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- methylindolizin
- rent
- carbonyl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE INDOLIZINA DE FORMULA (I) DONDE R1 ES H, HALOGENO, ALQUILO SUSTITUIDO OPCIONALMENTE CON -COOR5, ALQUENILO SUSTITUIDO OPCIONALMENTE CON -COOR5, ENTRE OTROS, EN DONDE R5 ES H, HALOGENOALQUILO, CICLOALQUILO, ENTRE OTROS; R2 ES H, ALQUILO O FENILO SUSTITUIDO OPCIONALMENTE CON ALQUILO; R3 Y R4 FORMAN JUNTO CON LOS ATOMOS DE CARBONO DEL NUCLEO FENILO AL QUE ESTAN UNIDOS UN HETEROCICLO NITROGENADO DE 6 MIEMBROS DE FORMULA (A), (B), ENTRE OTROS, DONDE Ra ES H, ALQUILO, HALOGENOALQUILO, ENTRE OTROS; Ra' ES H, ALQUILO, ENTRE OTROS; Rb ES H, ALQUILO, ENTRE OTROS; Rb' ES H, ALQUILO, CICLOALQUILO, FENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-{6-[(1-METOXI-2-METILINDOLIZIN-3-IL)CARBONIL]-2,4-DIOXO-1,4-DIHIDROQUINAZOLIN-3(2H)-IL}-N,N'-DIMETILACETAMIDA; 6-[(1-METOXI-2-METILINDOLIZIN-3-IL)CARBONIL]-3-[(3-METIL-1,2,4-OXADIAZOL-5-IL)METIL]QUINAZOLINA-2,4(1H,3H)-DIONA; ACIDO 3-{3-(2,4-DIOXO-3-PROPIL-1,2,3,4-TETRAHIDROQUINAZOLIN-6-IL)CARBONIL}-2-METILINDOLIZIN-1-IL}BENZOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LOS FACTORES DE CRECIMIENTO DE FIBROBLASTOS (FGF) SIENDO UTILES EN EL TRATAMIENTO DE ATEROSCLEROSIS, FIBROSIS HEPATICA, CANCER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1055477A FR2962438B1 (fr) | 2010-07-06 | 2010-07-06 | Derives d'indolizines, procedes de preparation et application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130386A1 true PE20130386A1 (es) | 2013-04-11 |
Family
ID=43382527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013000019A PE20130386A1 (es) | 2010-07-06 | 2011-07-04 | Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica |
Country Status (38)
Country | Link |
---|---|
US (1) | US8859544B2 (es) |
EP (1) | EP2590975B1 (es) |
JP (1) | JP5863788B2 (es) |
KR (1) | KR101797795B1 (es) |
CN (1) | CN103080112B (es) |
AR (1) | AR082768A1 (es) |
AU (1) | AU2011275426B2 (es) |
BR (1) | BR112013000306A2 (es) |
CA (1) | CA2805065C (es) |
CL (1) | CL2013000018A1 (es) |
CO (1) | CO6650361A2 (es) |
CR (1) | CR20130001A (es) |
CY (1) | CY1116945T1 (es) |
DK (1) | DK2590975T3 (es) |
DO (1) | DOP2012000321A (es) |
EA (1) | EA024160B1 (es) |
EC (1) | ECSP13012362A (es) |
ES (1) | ES2552850T3 (es) |
FR (1) | FR2962438B1 (es) |
GT (1) | GT201300001A (es) |
HR (1) | HRP20151162T1 (es) |
HU (1) | HUE026067T2 (es) |
IL (1) | IL223844A (es) |
MA (1) | MA34451B1 (es) |
MX (1) | MX2012015306A (es) |
MY (1) | MY163202A (es) |
NI (1) | NI201200191A (es) |
PE (1) | PE20130386A1 (es) |
PL (1) | PL2590975T3 (es) |
PT (1) | PT2590975E (es) |
SG (2) | SG186436A1 (es) |
SI (1) | SI2590975T1 (es) |
TN (1) | TN2012000609A1 (es) |
TW (1) | TWI494310B (es) |
UA (1) | UA109013C2 (es) |
UY (1) | UY33489A (es) |
WO (1) | WO2012004731A1 (es) |
ZA (1) | ZA201300100B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
FR2985258A1 (fr) * | 2011-12-28 | 2013-07-05 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
CN107383009B (zh) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
CN105263931B (zh) | 2013-04-19 | 2019-01-25 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
BR112017014770A2 (pt) * | 2015-01-08 | 2018-01-16 | Advinus Therapeutics Ltd | compostos bicíclicos, composições e aplicações médicas dos mesmos |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
EP3617205B1 (en) | 2015-02-20 | 2021-08-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US11253521B2 (en) | 2015-09-25 | 2022-02-22 | Ludwig Institute For Cancer Research Ltd | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators |
CN106045994A (zh) * | 2016-06-12 | 2016-10-26 | 上海大学 | 全氟烷基吲嗪衍生物及其合成方法 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
JP2021523118A (ja) | 2018-05-04 | 2021-09-02 | インサイト・コーポレイションIncyte Corporation | Fgfr阻害剤の塩 |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
AU2020366006A1 (en) | 2019-10-14 | 2022-04-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Fgfr阻害剤としての三環式ヘテロ環 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040116462A1 (en) | 2002-12-12 | 2004-06-17 | Mitsunori Ono | Indolizine compounds |
ES2291628T3 (es) | 2002-04-03 | 2008-03-01 | Bristol-Myers Squibb Company | Compuestos triciclicos a base de tiofeno y composiciones farmaceuticas que comprenden dichos compuestos. |
FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
FR2859997B1 (fr) | 2003-09-18 | 2006-02-03 | Sanofi Synthelabo | Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant. |
ATE500254T1 (de) | 2003-09-25 | 2011-03-15 | Janssen Pharmaceutica Nv | Die replikation von hiv hemmende purinderivate |
FR2865934B1 (fr) | 2004-02-05 | 2006-05-05 | Sanofi Synthelabo | Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne |
FR2883286B1 (fr) | 2005-03-16 | 2008-10-03 | Sanofi Aventis Sa | NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
FR2893616B1 (fr) | 2005-11-23 | 2008-01-04 | Sanofi Aventis Sa | Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant |
FR2896247B1 (fr) * | 2006-01-13 | 2008-02-29 | Sanofi Aventis Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
EP1891955A1 (en) * | 2006-07-24 | 2008-02-27 | Sanofi-Aventis | Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases |
-
2010
- 2010-07-06 FR FR1055477A patent/FR2962438B1/fr not_active Expired - Fee Related
-
2011
- 2011-07-04 KR KR1020137002986A patent/KR101797795B1/ko active IP Right Grant
- 2011-07-04 SG SG2012094579A patent/SG186436A1/en unknown
- 2011-07-04 US US13/808,483 patent/US8859544B2/en active Active
- 2011-07-04 PL PL11743363T patent/PL2590975T3/pl unknown
- 2011-07-04 MX MX2012015306A patent/MX2012015306A/es active IP Right Grant
- 2011-07-04 SG SG10201505282YA patent/SG10201505282YA/en unknown
- 2011-07-04 CA CA2805065A patent/CA2805065C/en not_active Expired - Fee Related
- 2011-07-04 EP EP11743363.1A patent/EP2590975B1/en active Active
- 2011-07-04 EA EA201291409A patent/EA024160B1/ru not_active IP Right Cessation
- 2011-07-04 DK DK11743363.1T patent/DK2590975T3/en active
- 2011-07-04 BR BR112013000306-5A patent/BR112013000306A2/pt not_active Application Discontinuation
- 2011-07-04 JP JP2013517655A patent/JP5863788B2/ja active Active
- 2011-07-04 WO PCT/IB2011/052953 patent/WO2012004731A1/en active Application Filing
- 2011-07-04 PE PE2013000019A patent/PE20130386A1/es not_active Application Discontinuation
- 2011-07-04 SI SI201130644T patent/SI2590975T1/sl unknown
- 2011-07-04 PT PT117433631T patent/PT2590975E/pt unknown
- 2011-07-04 AU AU2011275426A patent/AU2011275426B2/en not_active Ceased
- 2011-07-04 UA UAA201301382A patent/UA109013C2/en unknown
- 2011-07-04 ES ES11743363.1T patent/ES2552850T3/es active Active
- 2011-07-04 MY MYPI2012005603A patent/MY163202A/en unknown
- 2011-07-04 HU HUE11743363A patent/HUE026067T2/en unknown
- 2011-07-04 CN CN201180042948.8A patent/CN103080112B/zh active Active
- 2011-07-05 AR ARP110102399A patent/AR082768A1/es not_active Application Discontinuation
- 2011-07-06 UY UY0001033489A patent/UY33489A/es not_active Application Discontinuation
- 2011-07-06 TW TW100123928A patent/TWI494310B/zh not_active IP Right Cessation
-
2012
- 2012-12-19 TN TNP2012000609A patent/TN2012000609A1/en unknown
- 2012-12-20 DO DO2012000321A patent/DOP2012000321A/es unknown
- 2012-12-20 NI NI201200191A patent/NI201200191A/es unknown
- 2012-12-24 IL IL223844A patent/IL223844A/en active IP Right Grant
-
2013
- 2013-01-02 EC ECSP13012362 patent/ECSP13012362A/es unknown
- 2013-01-02 GT GT201300001A patent/GT201300001A/es unknown
- 2013-01-03 CL CL2013000018A patent/CL2013000018A1/es unknown
- 2013-01-04 CO CO13001349A patent/CO6650361A2/es not_active Application Discontinuation
- 2013-01-04 ZA ZA2013/00100A patent/ZA201300100B/en unknown
- 2013-01-07 CR CR20130001A patent/CR20130001A/es unknown
- 2013-02-05 MA MA35638A patent/MA34451B1/fr unknown
-
2015
- 2015-11-02 HR HRP20151162TT patent/HRP20151162T1/hr unknown
- 2015-11-18 CY CY20151101036T patent/CY1116945T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130386A1 (es) | Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica | |
AR114667A2 (es) | Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina | |
RS53939B1 (en) | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR APPLICATIONS AS ANTAGONISTS OF ADENOSIN A2A RECEPTOR | |
PE20130651A1 (es) | Derivados de imidazopiridina y su procedimiento de preparacion | |
PE20141974A1 (es) | Compuestos de heterociclilo | |
NZ596117A (en) | Novel anti-inflammatory agents | |
NZ605528A (en) | Ip receptor agonist heterocyclic compounds | |
PE20170502A1 (es) | ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6 | |
AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno | |
AR078732A1 (es) | Compuestos heterociclicos fusionados como moduladores del receptor de la orexina | |
AR078228A1 (es) | Inhibidores de cyp17 | |
PE20140234A1 (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1 | |
RS53226B (en) | NEW DERIVATIVES FENILIMIDAZOLA KAO INHIBITORS Enzyme PDE10A | |
PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
PE20160521A1 (es) | Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida | |
PE20070518A1 (es) | Compuestos de tiofeno bencimidazol como agentes inhibidores de plk | |
PE20141010A1 (es) | Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
AR079498A1 (es) | Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
AR074676A1 (es) | Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa. | |
AR078733A1 (es) | Compuestos heterociclicos fusionados como moduladores del receptor de orexina | |
PE20061442A1 (es) | Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia | |
PE20170682A1 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias | |
PE20141351A1 (es) | Triazolopiridinas | |
PE20160240A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |